Inadequate glycaemic control and antidiabetic therapy among inpatients with type 2 diabetes in Guangdong Province of China.
- Author:
Yan BI
1
;
Jin-hua YAN
;
Zhi-hong LIAO
;
Yan-bing LI
;
Long-yi ZENG
;
Kuan-xiao TANG
;
Yao-ming XUE
;
Hua-zhang YANG
;
Lu LI
;
De-hong CAI
;
Ge WU
;
Fan ZHANG
;
Shao-da LIN
;
Zheng-hua XIAO
;
Da-long ZHU
;
Jian-ping WENG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; China; epidemiology; Diabetes Mellitus, Type 2; blood; drug therapy; Female; Glycated Hemoglobin A; analysis; Humans; Hyperglycemia; epidemiology; Hypoglycemic Agents; administration & dosage; Inpatients; Male; Middle Aged
- From: Chinese Medical Journal 2008;121(8):677-681
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDDiabetes mellitus has become epidemic in recent years in China. We investigated the prevalence of hyperglycaemia and inadequate glycaemic control among type 2 diabetic inpatients from ten university teaching hospitals in Guangdong Province, China.
METHODSInadequate glycaemic control in diabetic patients was defined as HbA1c = 6.5%. Therapeutic regimens included no-intervention, lifestyle only, oral antiglycemic agents (OA), insulin plus OA (insulin + OA), or insulin only. Antidiabetic managements included monotherapy, double therapy, triple or quadruple therapy.
RESULTSAmong 493 diabetic inpatients with known history, 75% had HbA1c = 6.5%. Inadequate glucose control rates were more frequently seen in patients on insulin + OA regimen (97%) than on OA regimen (71%) (P < 0.001), and more frequent in patients on combination therapy (81% - 96%) than monotherapy (75%) (P < 0.05). Patients on insulin differed significantly from patients on OA by mean HbA1c, glycemic control rate, diabetes duration, microvascular complications, and BMI (P < 0.01).
CONCLUSIONSThis study showed that glycaemic control of type 2 diabetic patients deteriorated for patients who received insulin and initiation time of insulin was usually delayed. It is up to clinicians to move from the traditional stepwise therapy to a more active and early combination antidiabetic therapy to provide better glucose control.